Skip to content

About DISS2027

2027ThemeDesignWebsiteImageFINAL

Clinical research is entering a period of rapid change as artificial intelligence, advanced analytics, and innovative trial designs create new possibilities for how evidence is generated, evaluated, and applied. At the same time, these approaches raise important statistical, scientific, and regulatory questions about how we improve efficiency without compromising rigor, reliability, or trust.

DISS2027 will bring together experts from academia, industry, and regulatory agencies to examine these questions and their implications for drug development. Sessions will address AI and machine learning applications in clinical research, digital twins and synthetic patients, Bayesian and adaptive methodologies, master protocols, causal inference, treatment effect heterogeneity, companion diagnostics, multiplicity strategies, data integration, and next-generation approaches to clinical trial design and analysis.

Beyond individual methods, we are interested in some of the larger questions these developments raise for our field. How can AI accelerate evidence generation while maintaining trust and reliability? What is the evolving role of statisticians in an increasingly automated world? How can modern trial designs improve development decisions and meet evolving regulatory expectations? The Symposium will feature an array of enriching experiences, including short courses, keynote addresses by industry leaders, engaging parallel sessions, and dynamic poster lightning talks.  

The Steering and Organizing Committee extend a warm welcome to all participants!
Please do not hesitate to let us know if you require any assistance during your stay in Durham.



The Duke Industry Statistics Symposium (DISS) is organized by the Department of Biostatistics and Bioinformatics, Duke University School of Medicine and several industry and non-profit partners. The first symposium was established in 2013 to discuss challenging issues and recent advances related to the clinical development of drugs, biologics and devices and to promote research and collaboration among statisticians from industry, academia, and regulatory agencies.


Department of Biostatistics & Bioinformatics Logo

Join Our Community of Sponsors

Connect your organization with a premier audience of statisticians, data scientists, industry leaders, and regulatory experts. Sponsoring the Duke Industry Statistics Symposium provides exceptional visibility, networking opportunities, and access to innovative ideas shaping the future of healthcare, technology, and data science.

Showcase your brand. Build meaningful connections. Support scientific innovation.

Journal of Biopharmaceutical Publication

The 2026 DISS Special Issue in the Journal of Biopharmaceutical Statistics, with the theme ‘From Insight to Impact: Statistical Innovation Driving Clinical Research in the AI Era’ based on the invited talks and submitted posters from DISS2026 is in production. 

Manuscripts are submitted through the Taylor & Francis Submission Portal.
Please add ‘[2026DISS]’ as a prefix to the manuscript title so that the submission can be properly identified for the special issue.

Important Dates:
Final accepted version deadline: January 15, 2027 (Email Anru Zhang to make him aware of your submission please.) 
Expected online publication: March 2027

All submissions will undergo the standard peer-review process for the Journal of Biopharmaceutical Statistics. Authors should expect a timely review process, with revisions generally requested within 1–2 months rather than the journal’s default timeline for regular submissions.
Best regards,
Hong Tian (BeOne Medicines -formerly BeiGene) and Anru Zhang (Duke)
Guest Editors, 2026 DISS Special Issue Journal of Biopharmaceutical Statistics

Journal of Biopharmaceutical Statistics Logo

The DISS2025 Special Issue co-edited by Dr. Zhaoyang Teng (Astellas) and Dr. Haitao Chu (Pfizer)
will be available soon. 

View the DISS2024 Special Issue co-edited by Dr. Shibing Deng (Pfizer) and Dr. Zhaoyang Teng (Astellas).

A special 'Thank You' to all of our editing teams!